Citations (12)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Bimal R. Shah, Eva Scholtus, Catherine Rolland, Ariane Batscheider, Jason N. Katz & Kent R. Nilsson$suffix/text()$suffix/text(). (2019) A rapid evidence assessment of bleed-related healthcare resource utilization in publications reporting the use of direct oral anticoagulants for non-valvular atrial fibrillation. Current Medical Research and Opinion 35:1, pages 127-139.
Read now
Read now
Articles from other publishers (11)
Adenike R Adelakun, Ricky D Turgeon, Mary A De Vera, Kimberlyn McGrail & Peter S Loewen. (2023) Oral anticoagulant switching in patients with atrial fibrillation: a scoping review. BMJ Open 13:4, pages e071907.
Crossref
Crossref
Andrew B. Hughey, Xiaokui Gu, Brian Haymart, Eva Kline-Rogers, Steve Almany, Jay Kozlowski, Dennis Besley, Gregory D. Krol, Syed Ahsan, Scott Kaatz, James B. Froehlich & Geoffrey D. Barnes. (2018) Warfarin for prevention of thromboembolism in atrial fibrillation: comparison of patient characteristics and outcomes of the “Real-World” Michigan Anticoagulation Quality Improvement Initiative (MAQI2) registry to the RE-LY, ROCKET-AF, and ARISTOTLE trials. Journal of Thrombosis and Thrombolysis 46:3, pages 316-324.
Crossref
Crossref
Junya Zhu, G. Caleb Alexander, Saman Nazarian, Jodi B. Segal & Albert W. Wu. (2018) Trends and Variation in Oral Anticoagulant Choice in Patients with Atrial Fibrillation, 2010-2017. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 38:9, pages 907-920.
Crossref
Crossref
Joris Komen, Tomas Forslund, Paul Hjemdahl & Björn Wettermark. (2017) Factors associated with antithrombotic treatment decisions for stroke prevention in atrial fibrillation in the Stockholm region after the introduction of NOACs. European Journal of Clinical Pharmacology 73:10, pages 1315-1322.
Crossref
Crossref
Kyung-Kuk Hwang, Sang-Yong Eom, Sang Yeub Lee, Sang Min Kim, Myeong-Chan Cho, Young Jo Kim, Ki Bae Seung, Myung Ho Jeong & Jang-Whan Bae. (2017) Atrial Fibrillation on Admission Is Related With Higher Mortality in ST-Segment Elevation Myocardial Infarction Patients. International Heart Journal 58:4, pages 486-494.
Crossref
Crossref
Seo Hyon BaikInmaculada HernandezYuting Zhang. (2016) Evaluating the Initiation of Novel Oral Anticoagulants in Medicare Beneficiaries. Journal of Managed Care & Specialty Pharmacy 22:3, pages 281-292.
Crossref
Crossref
Mark H. Eckman. (2015) Decision-making about the use of non-vitamin K oral anticoagulant therapies for patients with atrial fibrillation. Journal of Thrombosis and Thrombolysis 41:2, pages 234-240.
Crossref
Crossref
Geoffrey D. Barnes, Eleanor Lucas, G. Caleb Alexander & Zachary D. Goldberger. (2015) National Trends in Ambulatory Oral Anticoagulant Use. The American Journal of Medicine 128:12, pages 1300-1305.e2.
Crossref
Crossref
Julie C. Lauffenburger, Joel F. Farley, Anil K. Gehi, Denise H. Rhoney, M. Alan Brookhart & Gang Fang. (2015) Factors Driving Anticoagulant Selection in Patients With Atrial Fibrillation in the United States. The American Journal of Cardiology 115:8, pages 1095-1101.
Crossref
Crossref
Kim Bouillon, Marion Bertrand, Géric Maura, Pierre-Olivier Blotière, Philippe Ricordeau & Mahmoud Zureik. (2015) Risk of bleeding and arterial thromboembolism in patients with non-valvular atrial fibrillation either maintained on a vitamin K antagonist or switched to a non-vitamin K-antagonist oral anticoagulant: a retrospective, matched-cohort study. The Lancet Haematology 2:4, pages e150-e159.
Crossref
Crossref
Todd C. Villines, Janet Schnee, Kathy Fraeman, Kimberly Siu, Matthew W. Reynolds, Jenna Collins & Eric Schwartzman. (2017) A comparison of the safety and effectiveness of dabigatran and warfarin in non-valvular atrial fibrillation patients in a large healthcare system. Thrombosis and Haemostasis 114:12, pages 1290-1298.
Crossref
Crossref